The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building bloc...

A 70-year-old man developed severe periorbital edema secondary to imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ). Imatinib mesylate is a tyrosine kinase inhibitor with a high degree of specificity for the BCRABL, KIT, and platelet-derived growth factor receptor tyrosine kinases. It is thought that inhibition of platelet-derived growth factor receptor results in dis...

Abstract This invited Team Profile was created by the Tiwary group, University of Maryland, College Park (USA) and Seeliger Stony Brook University, New York (USA). They recently published an article on previously made observation through in-cell screening that blockbuster cancer drug Gleevec has same binding affinity, yet different dissociation kinetics against wild-type N368S-mutated Abl kinas...

Volume 5(6) 1000e123 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal The landmark decision to rejection of patent to anti-cancer drug ‘Glivec’ by Indian Supreme Court has catalysed range of debates around importance of innovation in research and development. The patent plea by Novartis for beta crystalline for of imanitib (i.e. glivec) was considered as an attempt to extend period...

The platelet-derived growth factor receptor (PDGFR) is a receptor tyrosine kinase overexpressed in a subset of solid tumors and therefore is the target of drugs inhibiting this function such as imatinib mesylate (Gleevec). Thus far, drug therapy has played a limited role in the treatment of localized prostate cancer (PCa). This study characterizes PDGFR-beta expression in a wide spectrum of PCa...